Anthony Marucci, President & CEO of Celldex Therapeutics Inc (CLDX, Financial), purchased 11,500 shares of the company on November 11, 2024, as reported in a recent SEC filing. Following this transaction, the insider now owns a total of 40,284 shares of Celldex Therapeutics Inc.
Celldex Therapeutics Inc is engaged in the development and commercialization of immunotherapies and other targeted biologics for the treatment of cancer and other difficult-to-treat diseases. The company's strategic focus on precision medicine has positioned it as a leader in the biopharmaceutical sector.
Over the past year, the insider has increased their holdings by 11,500 shares, with no recorded sales of shares during this period. This recent acquisition aligns with a broader trend within the company, which has seen a total of 1 insider buy and 11 insider sells over the past year.
Shares of Celldex Therapeutics Inc were priced at $26.82 on the day of the transaction. The company currently has a market cap of approximately $1.83 billion.
The stock's valuation relative to its GF Value of $44.20 suggests a price-to-GF-Value ratio of 0.61, indicating that the stock might be undervalued. The GF Value is calculated based on historical trading multiples, an adjustment factor from GuruFocus, and future business performance estimates from analysts.
This insider buying activity could be a signal to investors, especially considering the stock's current valuation metrics and recent performance trends.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
